Advertisement

Pharmacy World & Science

, Volume 31, Issue 4, pp 481–486 | Cite as

Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome

  • Juraporn PongwecharakEmail author
  • Nawatsanan Tengmeesri
  • Nongluck Malanusorn
  • Matshamon Panthong
  • Nantida Pawangkapin
Research Article

Abstract

Objectives (1) To determine the prevalence of metformin prescribing in type 2 diabetes with a contraindication and (2) to explore whether metformin use on top of contraindications modified the risks of lactic acidosis, hospitalization, and death in type 2 diabetes. Setting Ambulatory diabetic clinics of the secondary-level care General Hospital of Hatyai district, Songkhla province, South Thailand. Method A cross-sectional study was carried out for the objective (1). A retrospective cohort study was applied to meet the objective (2). Out-patient medical case notes were reviewed for metformin use, number of hospitalizations, lactic acidosis cases, death cases, and the presence of contraindications, which were limited to: (1) chronic renal impairments, (2) chronic liver diseases, and (3) cardiac failure. Only documented diagnoses of the above conditions were counted. Main outcome measure The prevalence of metformin use in type 2 diabetes with a contraindication; odds ratios (ORs) of the occurrences of lactic acidosis, hospitalization, and death in type 2 diabetes with a contraindication modified by metformin use. Results A total of 1,630 type 2 diabetic outpatients were identified; 19.3% (315/1,630) had at least one contraindication to metformin use, with chronic renal impairment being the most frequent risk (78%, 246/315). Of those with a contraindication, 84.4% (266/315) were metformin users. Compared to non-metformin users, there were no significant differences in the number of hospitalizations and deaths. No cases of lactic acidosis were evident. Metformin use in the presence of contraindications did not affect the risks of hospitalization (OR 0.73, 95% confidence interval [CI] 0.38–1.4, P = 0.34) or death (OR 0.58, 95% CI 0.11–3.15, P = 0.53). Other patient factors, such as the female gender or having diabetes-related complications, had significant influences on both outcomes. Conclusion The prevalence of type 2 diabetes receiving metformin despite having a contraindication was over 80%. However, metformin use in such conditions did not appear to increase the risks of hospitalization and death. No lactic acidosis was reported. Other patient factors than metformin affect the risks of hospitalization and death.

Keywords

Contraindication Death Hospitalization Lactic acidosis Metformin Renal impairments Thailand Type 2 diabetes 

Notes

Acknowledgements

We are grateful to Miss Jaruwee Kanjanakeereethamrong of the Department of Pharmacy at Songkhla General Hospital for coordinating the data collection. Our thanks are also extended to Mr. Murray John McMurdo for the language proofreading.

Funding

This research project was supported by the annual research grant from the Faculty of Pharmaceutical Sciences and Prince of Songkla University.

Conflict of interest statement

None.

References

  1. 1.
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65. Erratum: p 1558.CrossRefGoogle Scholar
  2. 2.
    Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963–72.CrossRefPubMedGoogle Scholar
  3. 3.
    Selby JV, Ettinger B, Swain BE, Brown JB. First 20 months’ experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care. 1999;22:38–44.CrossRefPubMedGoogle Scholar
  4. 4.
    Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach. The COSMIC Approach Study. Diabetes Care. 2005;28:539–43.CrossRefPubMedGoogle Scholar
  5. 5.
    Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003;163:2594–602.CrossRefPubMedGoogle Scholar
  6. 6.
    Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006, Issue 1. Art. No.:CD002967. doi: 10.1002/14651858.CD002967.
  7. 7.
    Holstein A, Stumvoll M. Contraindications can damage your health—is metformin a case in point? Diabetologia. 2005;48:2454–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Tahrani AA, Varughese GI, Scarpello JH, Hanna FWF. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ. 2007;335:508–12.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Inzucchi SE, Masoudi FA, McGuire DK. Metformin in heart failure [observations]. Diabetes Care. 2007;30:e129.CrossRefPubMedGoogle Scholar
  10. 10.
    Roberts F, Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother. 2007;41:642–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345–51.CrossRefPubMedGoogle Scholar
  12. 12.
    Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin-associated lactic acidosis’. Diabetes Obes Metab. 2001;3:195–201.CrossRefPubMedGoogle Scholar
  14. 14.
    Stades AME, Heikens JT, Erkelens DW, Holleman F, Hoekstra JBL. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med. 2004;255:179–87.CrossRefPubMedGoogle Scholar
  15. 15.
    Ellis AK, Iliescu EA. Metformin-associated lactic acidosis in a low risk patient. Can J Clin Pharmacol. 2001;8:104–6.PubMedGoogle Scholar
  16. 16.
    Chu CK, Chang YT, Lee BJ, Hu SY, Hu WH, Yang DY. Metformin-associated lactic acidosis and acute renal failure in a type 2 diabetic patient. J Chin Med Assoc. 2003;66:505–8.PubMedGoogle Scholar
  17. 17.
    Brassøe R, Elkmann T, Hempel M, Gravholt CH. Fulminant lactic acidosis in two patients with type 2 diabetes treated with metformin. Diabet Med. 2005;22:1451–3.CrossRefPubMedGoogle Scholar
  18. 18.
    DePalo VA, Mailer K, Yoburn D, Crausman RS. Lactic acidosis. Lactic acidosis associated with metformin use in treatment of type 2 diabetes mellitus. Geriatrics. 2005;60:36, 39–41.PubMedGoogle Scholar
  19. 19.
    CMPMedica. MIMS drug information system, Thailand. 2008. Available online at: http://www.mims.com. Accessed 10 Nov 2008.
  20. 20.
    Sweileh WM. Contraindications to metformin therapy among patients with type 2 diabetes mellitus. Pharm World Sci. 2007;29:587–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M, et al. Frequency of inappropriate metformin prescriptions. JAMA. 2002;287:2504–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med. 2002;13:428.CrossRefPubMedGoogle Scholar
  23. 23.
    Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. A comprehensive resource for all clinicians and healthcare professionals. 2006–2007. 14th ed. Hudson: Lexi-Comp Inc.; 2006. p. 1091.Google Scholar
  24. 24.
    Millican S, Cottrell N, Green B. Do risk factors for lactic acidosis influence dosing of metformin? J Clin Pharm Ther. 2004;29:449–54.CrossRefPubMedGoogle Scholar
  25. 25.
    Emslie-Smith AM, Boyle DIR, Evans JMM, Sullivan F, Morris AD; DARTS/MEMO Collaboration. Contraindications to metformin therapy in patients with type 2 diabetes—a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162:434–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Kosachunhanun N, Benjasuratwong Y, Mongkolsomlit S, Rawdaree P, Plengvidhya N, Leelawatana R, et al. Thailand Diabetes Registry Project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. J Med Assoc Thai. 2006;89(Suppl 1):S66–71.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Juraporn Pongwecharak
    • 1
    Email author
  • Nawatsanan Tengmeesri
    • 1
  • Nongluck Malanusorn
    • 1
  • Matshamon Panthong
    • 1
  • Nantida Pawangkapin
    • 1
  1. 1.Faculty of Pharmaceutical SciencesPrince of Songkla UniversityHatyaiThailand

Personalised recommendations